Table 6.
Distribution of 378 observed minus expected cases between −1 and 10 years after biopsy according to cancer diagnosis (%)
| Cancer Diagnosis | Number | MCD | End | FSGS | MesPGN | MN | MPGN | FSPGN | Focal | NCGN | Unclassified | ANCAV | Typical GN in the literature [4] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lung | 37 | 8 | 6 | 16 | 17 | 23 | 11 | 6 | MN, MCD, MPGN, MesPGN, FSGS, NCGN | ||||
| Prostate | 33 | 16 | 20 | 28 | 15 | 8 | MCD, NCGN | ||||||
| Renal | 30 | 16 | 78 | NCGN, MesPGN, MCD, FSGS, MPGN | |||||||||
| Non-Hodgkin | 22 | 15 | 30 | 36 | 6 | MN, MCD, MPGN, FSGS, NCGN | |||||||
| Myeloma | 37 | 7 | 5 | 17 | 8 | 55 | |||||||
| Leukemia | 15 | 16 | 23 | 10 | 10 | 22 | 19 | MN, MCD, MPGN, FSGS, NCGN | |||||
| Skin (non-melanoma) | 152 | 7 | 6 | 16 | 12 | 8 | 10 | 12 | 11 | 10 | MN | ||
| Unclassified | 56 | 11 | 20 | 19 | 5 | 6 | 26 |
Cancer diagnoses with significantly raised incidence only. Negative figures excluded for this analysis. Only figures > 5% shown. MCD: minimal change disease
MN membranous nephropathy, FSGS focal segmental glomerulosclerosis, MesPGN mesangioproliferative GN, MPGN Membranoproliferative GN, FSPGN focal segmental proliferative GN, NCGN necrotizing and crescentic GN